(EN) A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab Versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting
KEYNOTE-C93 (GOG-3064/ENGOT-en15)
NCT05173987
 Actif en recrutement
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
 SITE GLEN
|
|
Phuong-Nam (Nathalie) Nguyen
514-934-1934 poste 31975
|
Étude de phase III à répartition aléatoire et à double insu évaluant le pembrolizumab par rapport à un placebo en association avec une chimiothérapie adjuvante avec ou sans radiothérapie pour le traitement du cancer de l’endomètre à risque élevé nouvellement diagnostiqué après une chirurgie à visée curative
KEYNOTE-B21 / ENGOT-en11 / GOG-3053
NCT04634877
Actif en recrutement
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
Phuong-Nam (Nathalie) Nguyen
514-934-1934 poste 31975
|
(EN) A Phase II, Single-Arm Study of Giredestrant in Patients With Grade 1 Endometrial Cancer
EndomERA
NCT05634499
Actif en recrutement
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
|
(EN) A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy
MK-2870-005 (ENGOT-en23/GOG-3095)
NCT06132958
Actif en recrutement
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
Phuong-Nam (Nathalie) Nguyen
514-934-1934 poste 31975
|
(EN) A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
XPORT-EC-042
NCT05611931
Actif en recrutement
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
Phuong-Nam (Nathalie) Nguyen
514-934-1934 poste 31975
|
(EN) A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects With TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy
ENGOT en-21 (KRT-232-118)
NCT05797831
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
|
Maryse Gingras
418-525-4444 poste 67322
|
(EN) A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab Versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting
KEYNOTE-C93 (GOG-3064/ENGOT-en15)
NCT05173987
Actif en recrutement
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
|
France Gauthier
514-890-8000 poste 30921
|
(EN) A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
XPORT-EC-042
NCT05611931
Actif en recrutement
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
|
Josée Tremblay
514-890-8000 poste 30637
|
(EN) A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy
MK-2870-005 (ENGOT-en23/GOG-3095)
NCT06132958
Actif en recrutement
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
|
|
(EN) ATARI: ATr Inhibitor in Combination With Olaparib in Gynaecological Cancers With ARId1A Loss
ATARI
NCT04065269
Actif en recrutement
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
|
Lynda Abdelguerfi
514-890-8000 poste 30657
|
Groupe d'étude en oncologie du Québec